Axsome Therapeutics
AXSM
17 hedge funds and large institutions have $45.2M invested in Axsome Therapeutics in 2016 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 3 closing their positions.
200% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 3
55% more funds holding
Funds holding: 11 → 17 (+6)
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
5% less capital invested
Capital invested by funds: $47.7M → $45.2M (-$2.41M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.91M |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$316K |
| 3 |
JP Morgan Chase
New York
|
+$287K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$122K |
| 5 |
Morgan Stanley
New York
|
+$117K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$1.02M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$671K |
| 3 |
Millennium Management
New York
|
-$517K |
| 4 |
Goldman Sachs
New York
|
-$226K |
| 5 |
Bank of New York Mellon
New York
|
-$107K |
AXSM Hedge Fund Activity: Q1 2016 in Review
17 of the 3,767 institutional investors tracked by Wall St. Rank reported a position in Axsome Therapeutics (AXSM) for Q1 2016, worth a combined $45.2M — down 5.1% from $47.7M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new AXSM positions and 3 closed out — a net gain of 6 holders — while 4 added to existing stakes and 4 trimmed.
The largest buyer was Vanguard Group, opening a new position worth an estimated $1.91M. The largest seller was Sphera Funds Management, cutting an estimated $1.02M.
- 17 institutional investors held Axsome Therapeutics (AXSM) as of Q1 2016, up from 11 in Q4 2015.
- Funds reported $45.2M of Axsome Therapeutics stock for Q1 2016, down 5.1% quarter-over-quarter.
- 9 funds opened new Axsome Therapeutics positions in Q1 2016 and 3 closed out, a net change of +6 holders.
- The largest Axsome Therapeutics buyer in Q1 2016 was Vanguard Group, an estimated $1.91M added.
- The largest Axsome Therapeutics seller in Q1 2016 was Sphera Funds Management, an estimated $1.02M sold.
Based on aggregated 13F filings for Q1 2016.